Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Large Growth in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 2,273,103 shares, a growth of 56.9% from the July 15th total of 1,448,757 shares. Currently, 3.0% of the shares of the company are short sold. Based on an average trading volume of 835,918 shares, the short-interest ratio is presently 2.7 days.

Insider Transactions at Nautilus Biotechnology

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of Nautilus Biotechnology stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the sale, the insider directly owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. This trade represents a 83.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 41.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Nautilus Biotechnology during the 2nd quarter valued at $5,025,000. Millennium Management LLC grew its position in Nautilus Biotechnology by 5.4% during the fourth quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock valued at $1,989,000 after buying an additional 52,448 shares during the period. Sentinel Trust Co. LBA bought a new position in Nautilus Biotechnology during the fourth quarter valued at about $1,462,000. Geode Capital Management LLC increased its holdings in Nautilus Biotechnology by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock worth $1,094,000 after buying an additional 7,307 shares during the last quarter. Finally, Corient Private Wealth LLC increased its holdings in Nautilus Biotechnology by 860.0% during the second quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock worth $316,000 after buying an additional 390,000 shares during the last quarter. 50.71% of the stock is currently owned by hedge funds and other institutional investors.

Nautilus Biotechnology Price Performance

NAUT opened at $0.85 on Wednesday. Nautilus Biotechnology has a fifty-two week low of $0.62 and a fifty-two week high of $4.31. The firm has a market capitalization of $108.39 million, a price-to-earnings ratio of -1.89 and a beta of 0.87. The company’s 50 day moving average price is $1.62 and its two-hundred day moving average price is $2.32.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, July 28th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.00.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.